Henry E. Schea
President chez Genopoietic SA
Profil
Henry E.
Schea is currently the President & General Director at Genopoietic SA since 2009.
Prior to this, he worked at AVAX Technologies, Inc. as the Executive Director-Regulatory Affairs from 2011 to 2016.
He completed his undergraduate degree from the University of Massachusetts in 1976.
Postes actifs de Henry E. Schea
| Sociétés | Poste | Début |
|---|---|---|
Genopoietic SA
 Genopoietic SA BiotechnologyHealth Technology Part of AVAX Technologies, Inc., Genopoietic SA is a French company that researches and develops cell and gene therapy for cancer, autoimmune diseases, and orthopedics. The company is based in Paris, France. Genopoietic was acquired by AVAX Technologies, Inc. on August 24, 2000 for $198.62 million. | President | 21/10/2011 |
Anciens postes connus de Henry E. Schea
| Sociétés | Poste | Fin |
|---|---|---|
| AVAX TECHNOLOGIES, INC. | Conseiller Juridique Général | 01/04/2016 |
Formation de Henry E. Schea
| University of Massachusetts | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AVAX TECHNOLOGIES, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Genopoietic SA
Genopoietic SA BiotechnologyHealth Technology Part of AVAX Technologies, Inc., Genopoietic SA is a French company that researches and develops cell and gene therapy for cancer, autoimmune diseases, and orthopedics. The company is based in Paris, France. Genopoietic was acquired by AVAX Technologies, Inc. on August 24, 2000 for $198.62 million. | Health Technology |